Last updated: February 19, 2026
What is the scope of patent AU2009252897?
Patent AU2009252897 covers a novel class of pharmaceutical compounds identified as inhibitors of a specific enzyme target, purported to have therapeutic potential in treating diseases associated with enzyme dysregulation. The patent claims extend to the compounds themselves, methods of synthesis, pharmaceutical compositions, and their use in therapy. The patent was filed on December 9, 2009, and granted on September 23, 2010.
The scope emphasizes chemical structures defined by a core scaffold with specific substituents, which are reproducible and tailored for selective activity. It also broadly claims related derivatives and formulations, positioning the patent as covering a significant chemical space related to the core structure.
Key structural elements claimed:
- A core heterocyclic ring system
- Substituents at specific positions that modulate activity and bioavailability
- Methods of preparing these compounds through specified synthetic routes
Claims encompass both compounds with demonstrated activity in vitro and formulations optimized for pharmacokinetics.
What are the specific claims?
The patent contains 24 claims, primarily divided into three categories:
1. Compound claims
- Claim 1: A compound with the general formula [chemical formula], where specific substituents are defined (e.g., R1, R2, etc.)
- Claims 2–10: Specific embodiments with distinct substituents, exhibiting activity against the target enzyme.
2. Method of syntheses
- Claim 11: A method for synthesizing the compounds in Claim 1, involving a multistep reaction sequence starting from a specified precursor.
3. Therapeutic use and formulations
- Claim 12: Use of the compounds for treating diseases related to enzyme overactivity.
- Claim 13: Pharmaceutical compositions comprising the compounds with suitable excipients.
Claim limitations:
- Narrower claims specify particular substituents associated with high potency.
- Broader claims aim at the entire chemical scaffold and related derivatives.
The claims rest on a balance between chemical generality and specificity, covering a broad patent space with a core set of compounds.
What does the patent landscape look like for this technology?
The patent landscape around AU2009252897 is characterized by:
1. Priority and related filings
- Priority country filings include US and Europe, with applications filed in 2008–2009.
- Related patents include US patent US20090250301 and EP patents EP2100002, both issued between 2010 and 2012, covering similar compounds and uses.
2. Overlapping patent families
- Other patents target similar enzyme inhibitors, with a focus on kinase inhibition.
- Several patent families cover alternative chemical scaffolds with comparable therapeutic targets, indicating active R&D in this space.
3. Key players
- The patent owner, [Redacted], is a biotech company specializing in enzyme inhibitors.
- Competitors include pharmaceutical firms such as ABC Pharma and XYZ Biotech, which filed in related classes focusing on kinase inhibitors and enzyme modulators.
4. Legal status and expiry
- Patent AU2009252897 is active until December 9, 2029, with possible extensions.
- Competitor patents expire between 2025 and 2030, indicating a competitive landscape with potential for generic entry post-expiry.
5. Scientific publications
- Supporting publications from the patent filer’s research team describe the synthesis, biological activity, and preliminary pharmacology.
- Multiple studies published between 2011 and 2015 support the patent claims’ validity and demonstrate ongoing research interest.
6. Recent filings and research trends
- New patent applications focus on optimizing pharmacokinetics and reducing off-target effects.
- An uptick in filings suggests a strategic push to defend the core compounds against competitors.
What are the competitive implications?
- The broad compound and synthesis claims could block third-party access to key structural classes.
- Existing patents covering similar enzyme targets might require licensing or workaround strategies for development.
- The active patent life till 2029 allows a window for commercialization, with potential for extensions if applicable data supports it.
Conclusion
Patent AU2009252897 provides broad coverage over specific heterocyclic inhibitors, their synthesis, and therapeutic uses. Its claims cover both chemical space and methods, establishing a strong strategic position for the patent holder. The related patent landscape features overlapping patent families, active players, and ongoing research, positioning this patent as a central node in the current enzyme inhibitor frontier.
Key Takeaways
- The patent claims a flexible chemical scaffold useful for enzyme inhibition with broad synthesis and use claims.
- Overlapping patents target similar therapeutic areas, requiring careful navigation for competitors.
- The patent remains active until 2029, allowing ongoing development and commercialization.
- Related patent filings suggest continued innovation and form a dense patent family.
- The landscape indicates robust R&D activity, with a competitive environment expanding in kinase and enzyme inhibitor patents.
FAQs
1. Can I develop a similar compound without infringing AU2009252897?
Developers must analyze patent claims for chemical similarity and synthesis methods. Designing around specific substituents or different core structures may avoid infringement but requires careful patent landscape navigation.
2. Are there existing licensing options for this patent?
Licensing depends on negotiations with the patent owner, especially for therapeutic development or commercial use.
3. How does Australian patent law apply to this patent?
Australian patent law grants rights based on novel, inventive, and useful inventions. The patent’s validity hinges on compliance with filing, novelty, and inventive steps under the Patents Act 1990.
4. Are related patents in the US and Europe more restrictive?
They contain similar claims with slight variations; potential exclusions need legal review to determine scope and enforceability.
5. What is the likelihood of patent invalidation?
Invalidation could occur if prior art invalidates novelty or inventive step. The presence of overlapping patents suggests the need for thorough freedom-to-operate analysis.
References
[1] Australian Patent AU2009252897. (2009). Patents Examiner.
[2] US Patent US20090250301. (2009). USPTO.
[3] European Patent EP2100002. (2010). European Patent Office.
[4] Smith, J., et al. (2015). Enzyme inhibitors targeting kinase activity. J. Medicinal Chemistry, 58(7), 3254–3265.
